Glucose and metabolic health markers is closer to a research marker, so it should be read separately from a directly felt benefit.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
Disease-specific, biomarker, animal, or cell-study findings — not everyday felt benefits.
10 new papers were added in this period. No new risk signal was identified.
Standalone side-effect signals and combination cautions are listed separately.
No standalone side-effect or combination signal is currently clear enough to show from the collected papers. This does not mean there is no concern.
Paper IDs and full lists are private. Only study types and summaries are shown.
Vitamin D supplementation was safe and it protected against acute respiratory tract infection overall and patients who were very vitamin D deficient and those not receiving bolus doses experienced the most benefit.
This study shows proof-of-principle that specific nutritional supplementation alone might benefit geriatric patients, especially relevant for those who are unable to exercise.
Among persons at high risk for type 2 diabetes not selected for vitamin D insufficiency, vitamin D3 supplementation at a dose of 4000 IU per day did not result in a significantly lower risk of diabetes than placebo.
It is suggested that vitamin D supplementation does not prevent fractures or falls, or have clinically meaningful effects on bone mineral density, and there is little justification to use vitamin D supplements to maintain or improve musculoskeletal health.
The findings suggest that vitamin D supplementation does not confer cardiovascular protection and is not indicated for this purpose.
Vitamin D supplementation for five years, with or without omega 3 fatty acids, reduced autoimmune disease by 22%, while omega3 fatty acid supplementation with or with vitamin D reduced the autoimmune disease rate by 15% (not statistically significant).